2025 ASTCT - EBMT Pharmacy SIG Journal Club

Join the ASTCT Pharmacy SIG on Wednesday, April 30, from 12 – 1 p.m. CDT, for a special journal club session in collaboration with the EBMT. This webinar will consist of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session.

During the webinar, Drs. White and Nezalova-Henriksen will present two articles related to: (a) Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic HSCT for older patients with AML or MDS and (b) Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients. The articles that will be presented are copied below to read prior to the webinar.

This webinar is open to ASTCT members and non-members. Please note that this session will not offer any continuing education credits.

Presenters & Articles:

Olivia White, PharmD, BCOP

Clinical Pharmacy Specialist

UT Southwestern Medical Center

Article: Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Katerina Nezvalova-Henriksen, PhD

Associate Professor – Section for Pharmacology and Pharmaceutical Biosciences

University of Oslo

Article: Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison

Moderators:

ASTCT

Tatjana Grgic, PharmD, BCOP

Clinical Pharmacy Specialist

UNC Health

EBMT

Nick Duncan, FBOPA

Consultant Hematology Pharmacist

University Hospitals Birmingham NHS Foundation Trust